Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised EQT AB (publ) in connection with the entry into of a EUR 1,000,000,000 revolving credit facility agreement.
Mandate

Vinge has advised EQT AB (publ) in connection with the entry into of a EUR 1,000,000,000 revolving credit facility agreement.

December 22, 2020 Banking and Finance

The financing is intended to be used for EQT’s general corporate purposes, including supporting its growth initiatives and long-term strategy.

The agreement contains a possibility to connect pricing to EQT’s compliance with certain ESG-targets. The financing was arranged by Nordea and SEB and the syndicate of banks contained 13 global financial institutions.

The Vinge team primarily consisted of Louise Brorsson Salomon, Ludvig Wettergren och Rebecka Målquist.

 

Related

Vinge has advised Egetis Therapeutics in connection with a directed share issue

 Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025

Vinge worked with funds advised by Agilitas on the buy-out of Vivicta (previously Tietoevry Tech Services), including on the issuance of senior secured bonds and on entering into a super senior RCF

 Vinge, together with O’Melveny as lead counsel and Avance, worked with funds advised by Agilitas Private Equity LLP (“Agilitas”), the pan-European mid-market private equity firm, in their backing of Vivicta. The buy-out was previously announced on 24 March 2025 and closed on 2 September 2025.
October 03, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 671.5 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of approx. SEK 671.5 million before transaction costs.
October 03, 2025